Investigations of interferon-lambda for the treatment of cancer. (Q38347596)

PubMed publication ID

2 September 2017

1 reference

title

Investigations of interferon-lambda for the treatment of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

author name string

Andrew Stiff

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

William Carson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

publication date

6 February 2015

1 reference

PubMed publication ID

25661266

Journal of Innate Immunity

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

page(s)

243-250

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

Interferon lambda: a new sword in cancer immunotherapy

12 May 2020

cites work

1 reference

Interferon-lambda as a potential therapeutic agent in cancer treatment

21 January 2018

1 reference

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma

21 January 2018

1 reference

Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.

21 January 2018

1 reference

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

21 January 2018

1 reference

Interferon- Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family

21 January 2018

1 reference

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

21 January 2018

1 reference

An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity

21 January 2018

1 reference

Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3

21 January 2018

1 reference

Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling

21 January 2018

1 reference

IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity

21 January 2018

1 reference

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines

21 January 2018

1 reference

Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes

21 January 2018

1 reference

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

21 January 2018

1 reference

Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress

21 January 2018

1 reference

Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis

21 January 2018

1 reference

Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response.

21 January 2018

1 reference

IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells

21 January 2018

1 reference

Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth

21 January 2018

1 reference

The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma

21 January 2018

1 reference

Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).

21 January 2018

1 reference

Interferon-alpha in the treatment of multiple myeloma

21 January 2018

1 reference

Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms

21 January 2018

1 reference

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

21 January 2018

1 reference

Antitumor activity of IFN-lambda in murine tumor models

21 January 2018

1 reference

Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer

21 January 2018

1 reference

Antitumor activity of type I and type III interferons in BNL hepatoma model

21 January 2018

1 reference

Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells

21 January 2018

1 reference

Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents

21 January 2018

1 reference

Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer

21 January 2018

1 reference

Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells

21 January 2018

1 reference

Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women.

21 January 2018

1 reference

A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects.

21 January 2018

1 reference

Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects

21 January 2018

1 reference

Regulation of apoptosis by type III interferons.

21 January 2018

1 reference

Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10

21 January 2018

1 reference

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

IL-28 elicits antitumor responses against murine fibrosarcoma

21 January 2018

1 reference

12 December 2020

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

12 December 2020

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

12 December 2020

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast

1 reference

12 December 2020

Identifiers

DOI

10.1159/000370113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6738825&resulttype=core&format=json

12 May 2020

PubMed publication ID

25661266

1 reference